Abstract: The present invention provides an antigen-binding molecule (e.g. antibody) with improved cytosol-penetrating ability, the molecule comprising an amino acid substitutions on at least one selected from the group consisting of CDRL1, CDRL2 and CDRL3 in a light-chain variable region, or an antigen-binding fragment (antibody fragment) thereof; and pharmaceutical compositions comprising the antigen-binding molecule; methods for delivering the antigen-binding molecule specifically into the cytosol of a target cell; methods of removing, suppressing, or activating a cytosolic antigen in a target cell-specific manner by using the antigen-binding molecule; and pharmaceutical compositions for diagnosing, preventing, or treating a disease in a subject comprising the antigen-binding molecule.

Abstract: The present invention relates to anti-HLA-DQ2.5 antibodies and its use for the treatment of celiac disease. The present invention provides anti-HLA-DQ2.5 antibodies that have been modified. The anti-HLA-DQ2.5 antibodies of the invention have binding activity to complexes formed by HLA-DQ2.5 and a gluten peptide, but have substantially no binding activity to complexes formed by HLA-DQ2.5 and an irrelevant peptide. Furthermore, the antibodies of the invention are shown to have inhibitory effects on T cell activation by gluten peptides.

Abstract: The present invention relates to anti-HLA-DQ2.5 antibodies and its use for the treatment of celiac disease. The present invention provides anti-HLA-DQ2.5 antibodies that have been modified. The anti-HLA-DQ2.5 antibodies of the invention have binding activity to complexes formed by HLA-DQ2.5 and a gluten peptide, but have substantially no binding activity to complexes formed by HLA-DQ2.5 and an irrelevant peptide. Furthermore, the antibodies of the invention are shown to have inhibitory effects on T cell activation by gluten peptides.

Abstract: The present invention relates to anti-HLA-DQ2.5 antibodies and its use for the treatment of celiac disease. The present invention provides anti-HLA-DQ2.5 antibodies that have been modified. The anti-HLA-DQ2.5 antibodies of the invention have binding activity to complexes formed by HLA-DQ2.5 and a gluten peptide, but have substantially no binding activity to complexes formed by HLA-DQ2.5 and an irrelevant peptide. Furthermore, the antibodies of the invention are shown to have inhibitory effects on T cell activation by gluten peptides.

Abstract: The invention relates to cytosol penetrating antigen binding molecules containing cell surface antigen binding domains, cytosolic antigen binding domains and cytosol penetrating domains; pharmaceutical compositions comprising said antigen binding molecules; methods of delivering said antigen binding molecules specifically into cytosols of target cells; methods of depleting, suppressing or activating cytosolic antigens specifically in target cells by using said antigen binding molecules; and pharmaceutical compositions for preventing or treating diseases in patients comprising said antigen binding molecules. The invention also relates to cytosol penetrating antigen binding molecules containing cytosol penetrating domains and Fc regions, wherein the Fc regions comprising one or more amino acid modifications that enhance multimerization of said cytosol penetrating antigen binding molecules.

Abstract: In a non-limiting embodiment, the present invention relates to antigen-binding molecules containing an altered TRIM21-binding domain and having an altered cytosolic half-life; pharmaceutical compositions containing such an antigen-binding molecule; methods for using such an antigen-binding molecule; methods for increasing or decreasing the cytosolic half-life of an antigen-binding molecule containing a TRIM21-binding domain; and methods for producing an antigen-binding molecule containing an altered TRIM21-binding domain and having an increased or decreased cytosolic half-life. The present invention also relates to substitutions at specific positions in a TRIM21-binding domain that increase or decrease the cytosolic half-life of an antigen-binding molecule containing a TRIM21-binding domain.